Cargando…

Neoadjuvant chemotherapy in well-differentiated fetal adenocarcinoma: a case report

BACKGROUND: Fetal adenocarcinoma of the lung is a rare subtype of pulmonary adenocarcinoma with a relative estimated incidence of 0.5% or fewer of all lung cancers. Because of its extreme rarity, there have been no controlled clinical trials investigating treatment regimens for fetal adenocarcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Lkhoyaali, Sihame, Boutayeb, Saber, Ismaili, Nabil, Aitelhaj, Meriem, Ouchen, Fahd, Benosman, Abdellatif, Errihani, Hassan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017811/
https://www.ncbi.nlm.nih.gov/pubmed/24886749
http://dx.doi.org/10.1186/1756-0500-7-283
_version_ 1782480009984737280
author Lkhoyaali, Sihame
Boutayeb, Saber
Ismaili, Nabil
Aitelhaj, Meriem
Ouchen, Fahd
Benosman, Abdellatif
Errihani, Hassan
author_facet Lkhoyaali, Sihame
Boutayeb, Saber
Ismaili, Nabil
Aitelhaj, Meriem
Ouchen, Fahd
Benosman, Abdellatif
Errihani, Hassan
author_sort Lkhoyaali, Sihame
collection PubMed
description BACKGROUND: Fetal adenocarcinoma of the lung is a rare subtype of pulmonary adenocarcinoma with a relative estimated incidence of 0.5% or fewer of all lung cancers. Because of its extreme rarity, there have been no controlled clinical trials investigating treatment regimens for fetal adenocarcinoma and, as a result, there are no guidelines for management. CASE PRESENTATION: We report a case of a well-differentiated fetal adenocarcinoma, which is a variant of pulmonary blastoma, that is a low-grade malignancy and associated with a good prognosis. A 29-year-old Moroccan man presented with a well-differentiated fetal adenocarcinoma staged T3N0M0, who received 3 cycles of neoadjuvant chemotherapy followed by surgery, with no recurrence at 2 years follow-up. CONCLUSION: Fetal adenocarcinoma is a rare suptype of adenocarcinoma. Surgical resection is the treatment of choice for resectable disease. The role of chemotherapy in the neoadjuvant setting or adjuvant setting is not well defined.
format Online
Article
Text
id pubmed-4017811
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40178112014-05-13 Neoadjuvant chemotherapy in well-differentiated fetal adenocarcinoma: a case report Lkhoyaali, Sihame Boutayeb, Saber Ismaili, Nabil Aitelhaj, Meriem Ouchen, Fahd Benosman, Abdellatif Errihani, Hassan BMC Res Notes Case Report BACKGROUND: Fetal adenocarcinoma of the lung is a rare subtype of pulmonary adenocarcinoma with a relative estimated incidence of 0.5% or fewer of all lung cancers. Because of its extreme rarity, there have been no controlled clinical trials investigating treatment regimens for fetal adenocarcinoma and, as a result, there are no guidelines for management. CASE PRESENTATION: We report a case of a well-differentiated fetal adenocarcinoma, which is a variant of pulmonary blastoma, that is a low-grade malignancy and associated with a good prognosis. A 29-year-old Moroccan man presented with a well-differentiated fetal adenocarcinoma staged T3N0M0, who received 3 cycles of neoadjuvant chemotherapy followed by surgery, with no recurrence at 2 years follow-up. CONCLUSION: Fetal adenocarcinoma is a rare suptype of adenocarcinoma. Surgical resection is the treatment of choice for resectable disease. The role of chemotherapy in the neoadjuvant setting or adjuvant setting is not well defined. BioMed Central 2014-05-05 /pmc/articles/PMC4017811/ /pubmed/24886749 http://dx.doi.org/10.1186/1756-0500-7-283 Text en Copyright © 2014 Lkhoyaali et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Lkhoyaali, Sihame
Boutayeb, Saber
Ismaili, Nabil
Aitelhaj, Meriem
Ouchen, Fahd
Benosman, Abdellatif
Errihani, Hassan
Neoadjuvant chemotherapy in well-differentiated fetal adenocarcinoma: a case report
title Neoadjuvant chemotherapy in well-differentiated fetal adenocarcinoma: a case report
title_full Neoadjuvant chemotherapy in well-differentiated fetal adenocarcinoma: a case report
title_fullStr Neoadjuvant chemotherapy in well-differentiated fetal adenocarcinoma: a case report
title_full_unstemmed Neoadjuvant chemotherapy in well-differentiated fetal adenocarcinoma: a case report
title_short Neoadjuvant chemotherapy in well-differentiated fetal adenocarcinoma: a case report
title_sort neoadjuvant chemotherapy in well-differentiated fetal adenocarcinoma: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017811/
https://www.ncbi.nlm.nih.gov/pubmed/24886749
http://dx.doi.org/10.1186/1756-0500-7-283
work_keys_str_mv AT lkhoyaalisihame neoadjuvantchemotherapyinwelldifferentiatedfetaladenocarcinomaacasereport
AT boutayebsaber neoadjuvantchemotherapyinwelldifferentiatedfetaladenocarcinomaacasereport
AT ismailinabil neoadjuvantchemotherapyinwelldifferentiatedfetaladenocarcinomaacasereport
AT aitelhajmeriem neoadjuvantchemotherapyinwelldifferentiatedfetaladenocarcinomaacasereport
AT ouchenfahd neoadjuvantchemotherapyinwelldifferentiatedfetaladenocarcinomaacasereport
AT benosmanabdellatif neoadjuvantchemotherapyinwelldifferentiatedfetaladenocarcinomaacasereport
AT errihanihassan neoadjuvantchemotherapyinwelldifferentiatedfetaladenocarcinomaacasereport